Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2022
(Exact name of registrant as specified in its charter)
Delaware 001-40646 85-3383487
(State or other jurisdiction
of incorporation)
File Number)
(I.R.S. Employer
Identification No.)
18105 SE Mill Plain Blvd
Vancouver, WA 98683
(Address of principal executive offices, including zip code)
(360) 949-1041
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareABSIThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Transition of Andreas Busch, Ph.D.

On September 30, 2022, Andreas Busch, Ph.D. notified Absci Corporation (the “Company”) effective immediately upon his appointment as the Company’s Chief Innovation Officer (as described in Item 8.01 below) that he would resign from the Company’s Board of Directors and all committees thereof.

Transition of Matthew Weinstock, Ph.D.

In connection with Dr. Busch’s appointment as the Company’s Chief Innovation Officer, Matthew Weinstock, Ph.D., the Company’s Chief Technology Officer, will transition into a consultant role on October 4, 2022. The Company extends its gratitude to Dr. Weinstock for his dedicated services to the Company.

The Compensation Committee of the Board Of Directors approved entering into a separation agreement and general release of claims with Dr. Weinstock effective as of September 30, 2022 (the “Separation Agreement”). Pursuant to the Separation Agreement, in exchange for certain releases of claims, Dr. Weinstock’s full-time employment as Chief Technology Officer will continue through October 4, 2022 (the “Separation Date”), and he will be entitled to (i) severance pay of twelve (12) months of Dr. Weinstock’s current base salary payable in equal monthly increments on the Company’s regular payroll dates, (ii) reimbursement of employer contributions of COBRA premiums for up to twelve (12) months, and (iii) a prorated cash bonus amount equal to $145,125, less applicable deductions and withholdings.

Additionally, Dr. Weinstock will serve as a consultant to the Company for up to eight (8) months pursuant to a consulting agreement effective as of the Separation Date (the “Consulting Agreement”). Under the Consulting Agreement, Dr. Weinstock is entitled to an hourly rate for his consulting services. As of the Separation Date, Dr. Weinstock’s outstanding equity awards will cease vesting and any vested portion of such awards will remain exercisable during the term of the Consulting Agreement.

The foregoing descriptions of the Separation Agreement and Consulting Agreement do not purport to be complete and are qualified in their entireties by reference to the full text of the Separation Agreement and Consulting Agreement, which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2022.

Item 8.01. Other Events

On October 4, 2022, Absci Corporation announced the appointment of Andreas Busch, Ph.D., as Chief Innovation Officer. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits
Exhibit No.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Absci Corporation
Date: October 4, 2022By:/s/ Sean McClain
Sean McClain
Founder and CEO

Exhibit 99.1

Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

Dr. Busch transitions from Absci’s Board of Directors to Absci’s Executive Leadership team

With a proven track record advancing drugs from discovery to market, Dr. Busch brings world-class R&D expertise to Absci’s executive leadership team

VANCOUVER, Wash. and NEW YORK, October 04, 2022 – Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological data to design better therapeutics, faster, today announced the appointment of Andreas Busch, PhD, as Chief Innovation Officer, where he will be responsible for leading R&D, technical operations, and driving both Absci’s internal and partner programs. As a former pharma R&D executive, Dr. Busch brings substantial R&D expertise to Absci’s leadership team as a world-renowned leader in drug development that has led discovery efforts for some of the globe’s top pharma companies including Sanofi, Bayer, and Shire. His leadership has resulted in over 10 commercial drugs starting from bench to FDA approval with several more in late stage clinical development.

“Serving on Absci’s Board has solidified my conviction and belief that Absci is dismantling the paradigm of drug discovery with generative AI which will allow us to achieve our vision to go from discovering or finding drugs within existing libraries to creating drugs in silico on a computer,” said Dr. Busch. “To usher in this new reality, high-quality and high-throughput biological data is needed. Absci has addressed this data problem through its breakthrough wet lab technology that can interrogate millions-to-billions of protein-protein interactions in a given week. The integration of these wet lab data technologies with generative AI is critical for the evolution of drug discovery to drug creation which will enable patients access to higher efficacy drugs, faster. I couldn’t be more excited to join the team full time and make this a reality.”

“I’m honored and humbled to have this opportunity to work alongside someone as accomplished and well respected in drug development as Dr. Busch,” said Sean McClain, Founder and CEO of Absci. “With his extensive operational R&D expertise coupled with Absci’s generative AI drug creation platform, we are strongly positioned to redefine the drug discovery process and create better drugs for patients faster. I’m thrilled to welcome Dr. Busch to our team and look to this next chapter with confidence as we embark on the protein drug creation revolution.”

Prior to joining Absci, Dr. Busch served as Chief Scientific Officer and Chief Innovation Officer, Head of the Innovation Center at Cyclerion Therapeutics, Inc., an innovator in CNS biotherapeutics. Before Cyclerion, Dr. Busch served as Executive Vice President, Head of Research & Development and Chief Scientific Officer at Shire prior to their acquisition by Takeda. Prior to joining Shire, he held several senior leadership positions in his 13-year tenure at Bayer, most recently as Executive Vice President and Head

Exhibit 99.1
of Global Drug Discovery for Bayer Pharma in which he oversaw all functions and activities from target identification to Proof of Concept in patients. Dr. Busch was responsible for shaping Bayer’s overall R&D strategy, integrating Schering’s drug discovery R&D, and oversaw vast improvements in Bayer's research productivity. Earlier in his career, Dr. Busch was Global Head of Cardiovascular Research at Hoechst and Sanofi-Aventis. Dr. Busch has served as a member of numerous Supervisory and Scientific Boards of research institutions and companies, including the German Cancer Research Center, the University of Tübingen, the Max Delbrück Center, and the Max Planck Institute of Molecular Genetics, as well as Takeda and start-up companies, such as Omeicos and BerlinCures. He also holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe-University in Frankfurt, Germany. Dr. Busch received his license to practice Pharmacy and PhD in Pharmacology from the Johann-Wolfgang-Goethe-University, Frankfurt. He is the author of over 400 publications and abstracts, and he received the prestigious Sir Bernard Katz and Franz Volhard Awards for his work on renal and cardiac ion channels and transporters.

About Absci
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic™ proteins containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel.

Availability of Other Information about Absci
Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on Twitter, LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Absci Forward-Looking Statements
Certain statements relating to Absci in this press release that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “aim,” “continue,” “may,” “pursues,” “anticipates,” “plans,” “believes,” “forecast,” “objective,”

Exhibit 99.1
“goal,” “estimates,” “expects,” “progress,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding technology development efforts and the application of those efforts, advancements toward in silico drug design and creation, drug discovery and development activities, internal research and publication efforts, the effective incorporation of our technology in drug design, and corporate initiatives, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to effectively collaborate on strategic activities with our partners; along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise
Investor Contact:
Media Contact: